BPC-157 & TB-500 Peptide Blend "WOLVERINE STACK"

BPC-157 peptide, also referred to as Pentadecapeptide BPC-157 or Body Protection Compound 157, is a fully synthetic peptide that has been associated with a range of cellular functions and is considered to hold relevance in the healing of experimental injury models. It is thought to interact with cellular communication pathways, potentially influencing processes linked to recovery and tissue restoration. Some studies suggest that BPC-157 may also support angiogenesis and play a role in regulating inflammation-related mechanisms.(1)

Additionally, experimental findings have indicated that BPC-157 may contribute to the protection and regeneration of various cell types and tissues. Across multiple studies, the peptide has been proposed to assist in the repair of joint, tendon, and muscle tissue, as well as nerve tissue, highlighting its broad potential in tissue healing contexts.

TB-500 peptide, also known as synthetic thymosin beta-4 or TB-4, has been suggested in research to potentially support healing processes following injury, including those involving the brain and nervous system. Additional studies have indicated possible roles in wound healing and hair growth. TB-500 is a laboratory-derived analogue of thymosin beta-4 (Tβ4), a naturally occurring peptide found within thymus cells and encoded by the TMSB4X gene. Based on research into thymosin beta-4, TB-500 appears to influence cellular movement, differentiation, and tissue repair, likely through interactions with various cellular signalling pathways. Investigations have also suggested that TB-500 may promote angiogenesis, as well as broader cellular and tissue regeneration processes.(2)

Both BPC-157 and TB-500 are synthetic polypeptides, with TB-500 consisting of 43 amino acids, while BPC-157 is composed of 15 amino acids.(3)(4)

Overview

Based on research into Tβ4, TB-500 has been suggested to influence cellular motility through the modulation of actin protein dynamics. More specifically, it is thought to regulate the actin cytoskeleton and cellular migration by sequestering globular actin (G-actin). A distinct amino acid segment—[(17)LKKTETQ(23)]—is believed to function as the active site responsible for actin binding, potentially enhancing cell movement. This mechanism may contribute to improved wound healing processes.(5) Additionally, TB-500 has been associated with increased levels of microRNA-146a (miR-146a), which may act as a suppressive regulator of certain cellular signalling pathways, particularly those linked to inflammation-related cytokines such as interleukin-1 receptor-associated kinase 1 (IRAK1) and tumour necrosis factor receptor-associated factor 6 (TRAF6). Supporting this, researchers noted that “transfection of anti-miR-146a nucleotides reversed the inhibitory effect of Tβ4 on IRAK1 and TRAF6,” suggesting a potential anti-inflammatory mechanism of action for TB-500.(6)

BPC-157 peptide has been proposed to act through multiple biological pathways, including those involving nitric oxide (NO) production, regulation of cells involved in tissue repair, growth factors, and inflammatory responses. It is suggested that BPC-157 may interact with nitric oxide pathways, potentially offering protective effects on the endothelium while promoting angiogenesis through the formation of new vascular networks. Research also indicates that the peptide may enhance the expression of the early growth response 1 (EGR-1) gene, which is associated with cytokine production and growth signalling, and may assist in the early formation of extracellular matrix components such as collagen. Furthermore, its interaction with nerve growth factor 1-A binding protein-2 may contribute to inhibitory regulation of specific cellular elements.(7) As a result of these combined actions, the formation of new collagen-based tissue may be supported, potentially accelerating the wound healing process.(8)

Given that both TB-500 and BPC-157 appear to share overlapping pharmacological potential, it has been suggested that their combined use may enhance overall effects. In theory, processes that may occur with one peptide alone could potentially be amplified or occur more efficiently when both are utilised together.

Chemical Makeup

Molecular Formula:

  • BPC-157: C62H98N16O22
  • TB-500: C212H350N56O78S

Molecular Weight:

  • BPC-157: 1419.5 g/mol
  • TB-500: 4963 g/mol

Other Known Titles

  • BPC-157: Body Protection Compound-157
  • TB-500: Thymosin Beta-4
Research and Clinical Studies

At present, there are no known research or clinical studies in which TB-500 and BPC-157 have been administered together within the same experimental framework or evaluated in combination using a single test model. The available literature instead focuses on examining the effects of each peptide independently.

Outlined below are studies that investigate the potential actions of each peptide on an individual basis.

BPC-157 & TB-500 Blend and Tissue Repair

In one study involving Tβ4 conducted in 1999,(9) experimentally wounded murine models were used, with half of the subjects receiving saline and the remaining group administered TB-500 peptide. The primary objective was to evaluate the peptide’s potential role in tissue repair. Four days following treatment, researchers reported that the TB-500 group demonstrated an approximate 41% increase in re-epithelialisation, referring to the formation of new epithelial cells to cover the wound surface. By day seven, wounds treated with TB-500 were observed to have contracted by at least 11% more than those treated with saline. The authors concluded that “these results suggest that Tβ4 is a potent wound healing factor with multiple activities...”

  • In a separate clinical trial conducted in 2006,(10) 72 subjects with pressure ulcers were studied to assess the potential of thymosin beta 4 (an analogue of TB-500) in wound healing. This randomised, double-blind study divided participants into two groups: one receiving a placebo over 84 days, and the other administered varying concentrations of the peptide daily for the same duration. At the conclusion of the study period, observations indicated that the ulcers in the treatment group exhibited signs consistent with progression in the healing process.
  • In a BPC-157 study,(11) three experimental murine models with induced wounds—both acute and chronic—were examined. These models were divided into two groups, with one receiving a placebo and the other administered the BPC-157 peptide. Following the experiment, histological analysis revealed that the BPC-157 group demonstrated a notably higher presence of collagen formation and blood vessel development compared to the control group.
BPC-157 & TB-500 Blend and Ligaments

In one study, (12) the medial collateral ligament (MCL) of murine models was surgically transected. Following the procedure, all subjects were treated with a fibrin sealing agent, while a subset also received thymosin beta 4 (TB-500). Four weeks post-surgery, researchers reported that the healing tissue in the peptide-treated group displayed more uniformly arranged and evenly spaced collagen fibres. These collagen structures were also observed to be wider in comparison to those in the control group. Additionally, the mechanical integrity of the regenerating tissue—particularly within the femur–medial collateral ligament–tibia complex—appeared to be enhanced in the TB-500 group relative to controls.

Another study suggested that BPC-157 may contribute to connective tissue recovery, potentially by stimulating the growth of tendon explants. The findings indicated that the peptide may also improve cellular resilience under oxidative stress conditions, possibly through the promotion of F-actin formation, as demonstrated by FITC-phalloidin staining. BPC-157 was further observed to enhance the in vitro migration of tendon fibroblasts, as measured through transwell migration assays, and to accelerate their dispersion across culture surfaces. The study also explored the involvement of the FAK–paxillin signalling pathway, which is associated with integrin-mediated cellular communication. Western blot analysis indicated increased phosphorylation of both FAK and paxillin in the presence of BPC-157, while total protein levels remained unchanged, suggesting activation of existing signalling components rather than increased protein expression.(8)

BPC-157 & TB-500 Blend and Muscle

A study(13) was conducted on murine models with experimentally induced injury to the gastrocnemius muscle complex. These models were initially administered corticosteroids, which were reported to exacerbate muscle damage. The subjects were then divided into two groups: one receiving a placebo and the other administered BPC-157 daily for a period of up to 14 days. Following the study, it was observed that the BPC-157-treated group appeared to demonstrate complete restoration of the damaged muscle tissue along with a return of functional capacity. In contrast, the placebo group showed no notable improvement in muscle condition.

TB-500 has also been suggested to play a role in muscle regeneration, particularly in relation to cardiac muscle cells. One study indicated that TB-500 may enhance myocardial resilience under hypoxic conditions and promote angiogenesis, potentially supporting cardiac tissue repair. Researchers have also proposed the possibility that cardiac fibroblasts may differentiate into cells resembling cardiomyocytes.(14) Furthermore, it was observed that when TB-500 is combined with cardiac reprogramming approaches, it may work synergistically to reduce cellular damage and support regeneration by activating intrinsic cardiac repair mechanisms. Additional findings from murine models involving coronary artery ligation suggested that TB-500 may increase the activity of integrin-linked kinase (ILK) and protein kinase B (Akt) within cardiac tissue, potentially improving early cardiomyocyte survival and overall cardiac function.(15) Researchers also noted that TB-500 may facilitate the migration of myocardial and endothelial cells in the developing fetal heart, with this functional capacity appearing to persist in mature cardiomyocytes.

BPC-157 & TB-500 Peptide Blend is available for research and laboratory purposes only. Please speak to our friendly research team to find out more and for sourcing options.

References:

  1. Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533.  https://doi.org/10.3389/fphar.2021.627533

  2. Maar, K., Hetenyi, R., Maar, S., Faskerti, G., Hanna, D., Lippai, B., Takatsy, A., & Bock-Marquette, I. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells, 10(6), 1343.  https://doi.org/10.3390/cells10061343

  3. National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem,  https://pubchem.ncbi.nlm.nih.gov/compound/132558700

  4. National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem,  https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157

  5. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812.  https://pubmed.ncbi.nlm.nih.gov/18480812/

  6. Santra, M., Zhang, Z. G., Yang, J., Santra, S., Santra, S., Chopp, M., & Morris, D. C. (2014). Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. The Journal of biological chemistry, 289(28), 19508–19518.  https://doi.org/10.1074/jbc.M113.529966

  7. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1

  8. Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010.  https://pubmed.ncbi.nlm.nih.gov/21030672/

  9. Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X,  https://www.sciencedirect.com/science/article/pii/S0022202X15405950

  10. Study of Thymosin Beta 4 in Patients With Pressure Ulcers.  https://www.clinicaltrials.gov/ct2/show/NCT00382174

  11. S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/

  12. Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026.  https://pubmed.ncbi.nlm.nih.gov/23523891/

  13. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676.  https://pubmed.ncbi.nlm.nih.gov/20190676/

  14. Srivastava, D., Ieda, M., Fu, J., & Qian, L. (2012). Cardiac repair with thymosin β4 and cardiac reprogramming factors. Annals of the New York Academy of Sciences, 1270, 66–72.  https://doi.org/10.1111/j.1749-6632.2012.06696.x

  15. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472.  https://doi.org/10.1038/nature03000

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

BPC-157 & TB-500 Peptide Blend "WOLVERINE STACK"